罕见但相关: 胺诱导的囊炎 - 对成药物的深入审查
1Addenbrooke's Hospital - Urology, Cambridge, UK.
Addiction (Abingdon, England)
|April 4, 2025
概括
胺诱导性囊炎或胺膀是一种严重的膀并发症,是由成性胺使用引起的. 对于患有物质使用障碍的患者来说,早期诊断和管理至关重要.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 成 药物 药物 药物 药物
- 毒理学 毒理学 毒理学
背景情况:
- 胺,一种分离性麻醉剂,越来越多地用于娱乐.
- 性胺使用与严重的尿路并发症有关.
- 胺诱导的囊炎 (胺膀) 是一个日益严重的公共卫生问题.
研究的目的:
- 为提供胺诱导囊炎的全面概述.
- 详细介绍其病理生理学,临床表现,诊断和管理.
- 讨论对成治疗和患者护理的影响.
主要方法:
- 文学评论整合了英国泌尿外科医生协会的共识.
- 分析关于胺囊炎和物质使用障碍的当前研究.
- 综合有关病理生理学,临床发现和治疗策略的信息.
主要成果:
- 胺囊炎呈现出各种尿路症状,并可能导致膀严重受损.
- 诊断需要一个高的怀疑指数在患者有过胺滥用史.
- 管理包括膀保护,停止服用胺和多学科护理.
结论:
- 胺激素诱导的囊炎是一种严重的,潜在的不可逆转的疾病,需要迅速识别.
- 综合管理策略对于解决膀状况和潜在的物质使用障碍至关重要.
- 需要进一步的研究来优化长期治疗结果和预防.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
144
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
144
Drug Abuse and Addiction: Pharmacological Phenomena
413
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
413
CNS Depressants: Barbiturates and Benzodiazepines
184
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
184
Opioid Analgesics: Synthetic and Semisynthetic Opioids
185
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
185
Analgesia and Pain Management
403
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
403
Drugs for Treatment of Diarrhea-Predominant IBS
126
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126


